CredoScientia - Bibliothèque

[Translational therapeutic strategies and timing of surgery for peritoneal metastasis in colorectal cancer].

Peritoneal metastasis from colorectal cancer is characterized by aggressive biological behavior, rapid disease progression, and poor overall prognosis, making it one of the most challenging conditions…

Thérapies de Conversion

Liu, L., Hu, Y. T., Kong, X. X., Zhu, A. K., Sun, L. F., & Wang, J. (2026). [Translational therapeutic strategies and timing of surgery for peritoneal metastasis in colorectal cancer].. Zhonghua Wei Chang Wai Ke Za Zhi, 29(5), 636-647. https://doi.org/10.3760/cma.j.cn441530-20260212-00087

25/05/2026 Lire →

[Efficacy of conversion therapy and prognostic factors in patients with synchronous gastric cancer liver metastasis].

To investigate the efficacy of conversion therapy and prognostic factors in patients with synchronous gastric cancer liver metastasis (GCLM), and to evaluate the clinical value of the Chinese Classif…

Thérapies de Conversion

Li, B., Deng, R., Liu, Y., Wang, X. J., Zhang, L., Wu, L. L., Tian, Y., Zheng, X. J., & Liang, H. (2026). [Efficacy of conversion therapy and prognostic factors in patients with synchronous gastric cancer liver metastasis].. Zhonghua Wei Chang Wai Ke Za Zhi, 29(5), 653-661. https://doi.org/10.3760/cma.j.cn441530-20260222-00092

25/05/2026 Lire →

[Surgical strategies following conversion therapy for metastatic colorectal cancer].

Curative resection following conversion therapy has become a key strategy for improving the prognosis of patients with advanced colorectal cancer (CRC). Based on the latest evidence from clinical stud…

Thérapies de Conversion

Cong, Z. Y., & Xu, Y. (2026). [Surgical strategies following conversion therapy for metastatic colorectal cancer].. Zhonghua Wei Chang Wai Ke Za Zhi, 29(5), 627-635. https://doi.org/10.3760/cma.j.cn441530-20260313-00118

25/05/2026 Lire →

[Precise prevention and treatment strategies for surgical complications after conversion therapy for gastric cancer].

Conversion therapy offers a potential curative opportunity for patients with initially unresectable gastric cancer. However, the consequent systemic and local pathophysiological changes significantly …

Thérapies de Conversion

Zhou, Y. B. (2026). [Precise prevention and treatment strategies for surgical complications after conversion therapy for gastric cancer].. Zhonghua Wei Chang Wai Ke Za Zhi, 29(5), 621-626. https://doi.org/10.3760/cma.j.cn441530-20260302-00105

25/05/2026 Lire →

Conversion therapy with arterial reconstruction: Redefining the resect-ability of locally advanced pancreatic cancer.

Thérapies de Conversion

Wang, F. F., Zhou, L., Dai, X. D., Liu, Q. P., Pan, B., Lang, R., He, Q., & Lyu, S. C. (2026). Conversion therapy with arterial reconstruction: Redefining the resect-ability of locally advanced pancreatic cancer.. Hepatobiliary Pancreat Dis Int. https://doi.org/10.1016/j.hbpd.2026.05.001

11/05/2026 Lire →

ASO Author Reflections: Radical Resection for HCC with PVTT After Second-Line Conversion Therapy.

Thérapies de Conversion

Tan, W., Wei, J., Luo, X., Zhong, J., Zhou, R., Chen, Y., & Shang, C. (2026). ASO Author Reflections: Radical Resection for HCC with PVTT After Second-Line Conversion Therapy.. Ann Surg Oncol. https://doi.org/10.1245/s10434-026-19784-x

11/05/2026 Lire →

Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trial.

Our previous findings demonstrated the promising antitumor activity and manageable safety of sintilimab-lenvatinib conversion therapy. The current study aimed to evaluate long-term survival outcomes i…

Thérapies de Conversion

Lu, S., Zhang, W., Li, J., Zhang, Z., Hu, B., Li, X., Cao, Y., Wang, Z., Wang, Z., Ye, H., Qu, B., Li, Y., Ma, G., Wan, T., Liu, Z., Liu, B., Xu, Y., Tang, H., Zhao, X., … Bian, X. (2026). Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trial.. Signal Transduct Target Ther, 11(1). https://doi.org/10.1038/s41392-026-02708-2

06/05/2026 Lire →

A Step Backward Regarding Conversion Therapy for LGBTQ+ Youth.

Thérapies de Conversion

Thomas, S. P. (2026). A Step Backward Regarding Conversion Therapy for LGBTQ+ Youth.. Issues Ment Health Nurs, 47(5), 427-428. https://doi.org/10.1080/01612840.2026.2662202

01/05/2026 Lire →

Pathological Complete Response in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Following Conversion Therapy With TACE, HAIC, Lenvatinib, and Sintilimab: A Case Report.

Hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) is an advanced disease with poor prognosis and limited treatment options. Conversion therapy integrating locoregional and systemic…

Thérapies de Conversion

Zhang, W., Shen, H., Wang, X., Gu, J., Shen, M., & Zhang, Q. (2026). Pathological Complete Response in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Following Conversion Therapy With TACE, HAIC, Lenvatinib, and Sintilimab: A Case Report.. Clin Case Rep, 14, e72711. https://doi.org/10.1002/ccr3.72711

01/05/2026 Lire →

Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab.

BACKGROUND: Conversion therapy, which seeks to achieve curative treatment following systemic therapy, is increasingly acknowledged in the management of unresectable hepatocellular carcinoma (HCC). How…

Thérapies de Conversion

Takeuchi, Y., Sue, M., Miyake, N., Adachi, T., Onishi, H., Kawanaka, M., Takaki, A., Nouso, K., Kariyama, K., Nakamura, S., Tanaka, E., Tada, T., Yasunaka, T., Kuwaki, K., Toshimori, J., Iwado, S., Moriya, A., Hagihara, H., Takabatake, H., … Otsuka, M. (2026). Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab.. Hepatol Res, 56(5), 830-839. https://doi.org/10.1111/hepr.70138

01/05/2026 Lire →

Conversion Therapy Based on TACE/HAIC-Based Treatment to Improve the Therapeutic Effect of Initially Unresectable Hepatocellular Carcinoma.

OBJECTIVES: The main objectives of this research are to evaluate the outcomes of patients with initially unresectable hepatocellular carcinoma (HCC) who received transcatheter arterial chemoembolizati…

Thérapies de Conversion

Lin, S., Song, Z., Chen, P., Yu, X., Xie, W., Hua, Y., Li, S., Shen, S., & Kuang, M. (2026). Conversion Therapy Based on TACE/HAIC-Based Treatment to Improve the Therapeutic Effect of Initially Unresectable Hepatocellular Carcinoma.. Liver Cancer, 15(2), 254-284. https://doi.org/10.1159/000547725

01/05/2026 Lire →

PD-1 inhibitors combined with tyrosine kinase inhibitors for conversion therapy in patients with unresectable hepatocellular carcinoma: a retrospective cohort study.

BACKGROUND: The majority of patients with hepatocellular carcinoma (HCC) are diagnosed at an advanced stage, precluding surgical resection. Studies have evaluated the use of programmed cell death prot…

Thérapies de Conversion

Liu, G., Guo, C., Li, X., Lv, Z., Du, J., & Gong, L. (2026). PD-1 inhibitors combined with tyrosine kinase inhibitors for conversion therapy in patients with unresectable hepatocellular carcinoma: a retrospective cohort study.. J Gastrointest Oncol, 17(2), 76. https://doi.org/10.21037/jgo-2026-1-0023

30/04/2026 Lire →